Celyad Oncology SA
CLYYF
$0.25
-$0.10-28.57%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -0.43% | 226.28% | -7.85% | -30.51% | 3.04% |
| Total Depreciation and Amortization | 0.38% | -145.94% | 7.92% | 48.00% | -3.07% |
| Total Amortization of Deferred Charges | -0.58% | -- | -- | -- | -3.00% |
| Total Other Non-Cash Items | 0.43% | -4,078.04% | 7.78% | 200.56% | 3.03% |
| Change in Net Operating Assets | 0.43% | -6,016.89% | 8.03% | 121.08% | 3.13% |
| Cash from Operations | 0.43% | -14.09% | -7.85% | -13.45% | 3.04% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -0.43% | -- | -- | -- | -2.44% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -0.43% | -- | -- | -- | -2.44% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 27.40% | 0.00% | 13.10% | 0.00% |
| Issuance of Common Stock | 0.00% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | 1,080.95% | 0.00% | -107.06% | 0.00% |
| Cash from Financing | -0.44% | 1,258.55% | -7.82% | -116.62% | -3.02% |
| Foreign Exchange rate Adjustments | 0.00% | 483.33% | 20.00% | 123.81% | 4.55% |
| Miscellaneous Cash Flow Adjustments | 0.00% | 200.00% | -20.00% | -200.00% | -16.67% |
| Net Change in Cash | -0.43% | 127.73% | -7.85% | -65.91% | 3.04% |